ATE556076T1 - Verbindungen zur hemmung von mitoseprogression - Google Patents

Verbindungen zur hemmung von mitoseprogression

Info

Publication number
ATE556076T1
ATE556076T1 AT07867449T AT07867449T ATE556076T1 AT E556076 T1 ATE556076 T1 AT E556076T1 AT 07867449 T AT07867449 T AT 07867449T AT 07867449 T AT07867449 T AT 07867449T AT E556076 T1 ATE556076 T1 AT E556076T1
Authority
AT
Austria
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
inhibiting
progression
Prior art date
Application number
AT07867449T
Other languages
German (de)
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE556076(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE556076T1 publication Critical patent/ATE556076T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07867449T 2006-11-16 2007-11-14 Verbindungen zur hemmung von mitoseprogression ATE556076T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
ATE556076T1 true ATE556076T1 (de) 2012-05-15

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07867449T ATE556076T1 (de) 2006-11-16 2007-11-14 Verbindungen zur hemmung von mitoseprogression

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2944639B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101110458B1 (enExample)
CN (2) CN103483343B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2086981T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2537451T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX343391B (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ597252A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2086981T3 (enExample)
PT (2) PT2497772E (enExample)
RS (2) RS53788B1 (enExample)
SG (2) SG176443A1 (enExample)
SI (2) SI2086981T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JP5684719B2 (ja) * 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
BR112012020557A8 (pt) * 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
JP5844358B2 (ja) * 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
EP3347355B1 (en) 2015-09-09 2022-07-13 Icahn School of Medicine at Mount Sinai Heterotricyclic sulfonamides as anti-cancer agents
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
US11340215B2 (en) 2016-02-26 2022-05-24 Japanese Foundation For Cancer Research Screening method of anticancer agent focused on function of HP1 and evaluation system
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP4504710A1 (en) 2022-04-07 2025-02-12 Eli Lilly and Company Process for making a kras g12c inhibitor
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
EP4547251A1 (en) 2022-06-30 2025-05-07 Eli Lilly and Company Kras g12c inhibitor for treating cancer
CN121941495A (zh) 2023-10-03 2026-04-28 武田药品工业株式会社 用于治疗小细胞肺癌的阿立塞替和紫杉醇
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
ES2191963T3 (es) * 1997-09-29 2003-09-16 Meiji Seika Kaisha Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU1651201A (en) 1999-12-06 2001-06-18 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
US6989385B2 (en) * 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
CN101084214A (zh) 2004-11-17 2007-12-05 迈卡纳治疗股份有限公司 激酶抑制剂
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EA200870117A1 (ru) 2005-12-23 2008-12-30 Смитклайн Бичам Корпорейшн Азаиндоловые ингибиторы аурора-киназ
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
EP2944639A1 (en) 2015-11-18
SG176443A1 (en) 2011-12-29
MX348568B (es) 2017-06-20
CY1112828T1 (el) 2016-02-10
HK1175777A1 (en) 2013-07-12
EP2497773B1 (en) 2015-02-25
CN101547924B (zh) 2013-09-25
PL2086981T3 (pl) 2012-09-28
KR20090091173A (ko) 2009-08-26
NZ611898A (en) 2015-01-30
EP2497772A1 (en) 2012-09-12
US9765076B2 (en) 2017-09-19
RS53788B1 (sr) 2015-06-30
CR10782A (es) 2009-06-24
EP2497772B1 (en) 2014-10-29
PH12012502057A1 (en) 2015-09-14
AU2007322046B2 (en) 2012-04-05
PH12012502057B1 (en) 2018-10-24
EP2944639B1 (en) 2017-01-04
US10836766B2 (en) 2020-11-17
MX343391B (es) 2016-11-04
HRP20120490T1 (hr) 2012-07-31
BRPI0718803B8 (pt) 2021-05-25
SG10201503350TA (en) 2015-06-29
SI2497772T1 (sl) 2015-03-31
US8026246B2 (en) 2011-09-27
JP2014055166A (ja) 2014-03-27
DK2086981T3 (da) 2012-08-06
HRP20150047T1 (en) 2015-03-13
WO2008063525A1 (en) 2008-05-29
JP2012006965A (ja) 2012-01-12
MA30988B1 (fr) 2009-12-01
TWI401255B (zh) 2013-07-11
ZA200903279B (en) 2010-07-28
EP2086981B1 (en) 2012-05-02
RS52313B (sr) 2012-12-31
US9988384B2 (en) 2018-06-05
ES2528793T3 (es) 2015-02-12
CN103483343A (zh) 2014-01-01
NZ597252A (en) 2013-06-28
PL2497772T3 (pl) 2015-05-29
IL198690A0 (en) 2010-02-17
JP5452811B2 (ja) 2014-03-26
JP5102839B2 (ja) 2012-12-19
KR20110113210A (ko) 2011-10-14
US20110312942A1 (en) 2011-12-22
US20190031662A1 (en) 2019-01-31
DK2497772T3 (en) 2015-01-19
NZ577042A (en) 2012-03-30
US20110312943A1 (en) 2011-12-22
HK1175778A1 (en) 2013-07-12
CA2669680A1 (en) 2008-05-29
CR20140544A (es) 2015-01-12
CR20140154A (es) 2014-07-23
KR101110458B1 (ko) 2012-03-13
CN103483343B (zh) 2016-06-01
AR064246A1 (es) 2009-03-25
TW200829589A (en) 2008-07-16
ES2537451T3 (es) 2015-06-08
GEP20125459B (en) 2012-03-26
HK1134672A1 (en) 2010-05-07
CA2669680C (en) 2012-04-10
MY153243A (en) 2015-01-29
HK1217699A1 (en) 2017-01-20
EP2086981A1 (en) 2009-08-12
SI2086981T1 (sl) 2012-12-31
US20240400567A1 (en) 2024-12-05
CN101547924A (zh) 2009-09-30
BRPI0718803A2 (pt) 2013-12-03
KR101342014B1 (ko) 2013-12-19
PT2497772E (pt) 2015-02-05
EA200970486A1 (ru) 2009-10-30
NO343338B1 (no) 2019-02-04
AU2007322046A1 (en) 2008-05-29
CL2007003244A1 (es) 2008-04-04
NO20091864L (no) 2009-06-15
BRPI0718803B1 (pt) 2020-11-17
EP2497773A1 (en) 2012-09-12
US20210214361A1 (en) 2021-07-15
ES2384123T3 (es) 2012-06-29
JP2010510215A (ja) 2010-04-02
EA015779B1 (ru) 2011-12-30
US20080167292A1 (en) 2008-07-10
US11958855B2 (en) 2024-04-16
UA94129C2 (ru) 2011-04-11
US20150166545A1 (en) 2015-06-18
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20

Similar Documents

Publication Publication Date Title
ATE556076T1 (de) Verbindungen zur hemmung von mitoseprogression
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
BRPI0714512A2 (pt) Compostos químicos
ATE524477T1 (de) Aziridinylepothilonverbindungen
EP2089308A4 (en) DONOR
ATE540954T1 (de) Aminoheterocyclische verbindungen
BRPI0815042A2 (pt) Compostos de pirazol
ATE554776T1 (de) Antivirale phosphinatverbindungen
EP2022730A4 (en) CONTAINER OF SUBSTRATES
ATE435198T1 (de) Orthosubstituierte aryl- oder heteroarylamidverbindungen
DE602007007219D1 (de) Selements zur zeitmessung
BRPI0720097A2 (pt) Compostos de fosfonato
EP3628321C0 (en) COMPOUNDS FOR ENHANCEMENT OF ERYTHROPOIESIS
DE602007007157D1 (de) Kodierer zur Verschiebungsbestimmung
DK1994062T3 (da) Aryl/alkyl-vinylsulfonhyaluronsyrederivater
DE602007005747D1 (de) System zur Entfernung von Kalkablagerungen
DE602006020089D1 (de) Verfahren zur CVI
ATE445586T1 (de) Terphenylderivate zur alzheimerbehandlung
PT2792662T (pt) Compostos de morfinano
BRPI0811860A2 (pt) Compostos de (fenil)imidazolil)metilheteroarila
DE602006004185D1 (de) Verfahren zur herstellung geschützter amidine
BRPI0719883A2 (pt) Inibidores de quinase
SE530154C8 (sv) Saltblandning
ITVI20060206A1 (it) Imbragatura per calzature
EP2043933A4 (en) FOOD MECHANISM FOIL SHEET